Is Tilray Stock a Buy?_老虎社区_美港股上老虎

Is Tilray Stock a Buy?

Motley Fool2021-03-08

It's not the worst idea to invest in the world's largest marijuana grower by revenue.Canadian weed giant Tilray was on a tear for much of 2020. Despite the stock market woes of the past week, its ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

ruii
·2021-03-08
Really worth?
回复
2
举报
收起
- CSYNCTP06:
  Not really
  2021-03-08
  回复
  举报
ChickenRice
·2021-03-08
$Tilray Inc.(TLRY)$getting ready for 4/20, also known as week day.With more states in the U.S. getting Marijuana legalised both recreational and medicinal use. I see no exception that this is a far fetch long term investment in the long run.
回复
8
举报
收起
- ChickenRice:
  4月20日是杂草日. 😅
  2021-03-09
  回复
  举报
- penger_1247:
  拿住五年应该有不错的回报
  2021-03-11
  回复
  举报
- AbC:
  4月20日是什么日子？
  2021-03-09
  回复
  举报
查看更多 1 条评论
weijie123
·2021-03-08
Good
回复
点赞
举报
vbjvvbb
·2021-03-08
Yes
回复
点赞
举报
vbjvvbb
·2021-03-08
Omg
回复
点赞
举报
KLS
·2021-03-08
Pls like n comment
回复
1
举报
elite
·2021-03-08
Please help to comment
回复
2
举报
收起
- KLS:
  pls like n cimment
  2021-03-08
  回复
  举报
- Mm101:
  Yes
  2021-03-09
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2117666651?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-03-08 14:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2117666651","market":"us","top_or_hot":-1,"title":"Is Tilray Stock a Buy?","media":"Motley Fool","content":"<div>\n<p>It's not the worst idea to invest in the world's largest marijuana grower by revenue.Canadian weed giant Tilray was on a tear for much of 2020. Despite the stock market woes of the past week, its ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/07/is-tilray-stock-a-buy/\">网页链接</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Tilray Stock a Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Tilray Stock a Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-08 14:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/07/is-tilray-stock-a-buy/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It's not the worst idea to invest in the world's largest marijuana grower by revenue.Canadian weed giant Tilray was on a tear for much of 2020. Despite the stock market woes of the past week, its ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/07/is-tilray-stock-a-buy/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.fool.com/investing/2021/03/07/is-tilray-stock-a-buy/","article_id":"2117666651","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2117666651","pubTimestamp":1615185538,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"It's not the worst idea to invest in the world's largest marijuana grower by revenue.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Tilray的股票是买入吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLRY":0.9},"content_text":"It's not the worst idea to invest in the world's largest marijuana grower by revenue.Canadian weed giant Tilray was on a tear for much of 2020. Despite the stock market woes of the past week, its shares have gone up nearly 60% over the past 12 months, making it one of the top performers in the industry benchmark Horizons Marijuana Life Sciences Index ETF, which returned 46% over the same period.Investors have a lot to be thrilled about with Tilray, the most promising of which is its substantial international presence, which will become a game-changer as more countries legalize the recreational and medical use of cannabis. Let's investigate how Tilray can capitalize on marijuana's entry to the mainstream.Image source: Getty Images.An exciting cannabis companyLast year, Tilray grew its revenue by 26% from 2019, reaching $210.5 million. It is also near the finish line in terms of achieving profitability. During Q4 2020 (ended Dec. 31), its net loss narrowed to just $3 million from $219.8 million in the prior-year quarter.The company terminated a bulk cannabis supply agreement, and as a result, only managed to sell 6,901 kilograms (kg) of dried cannabis in Q4 2020 compared to 15,039 kg in Q4 2019. However, Tilray is seeing more demand for high-priced, highly tetrahydrocannabinol (THC)-potent adult brands. The net selling price of its cannabis went up to $5.97 per gram compared to $1.88 a year earlier. Also, it brought its total store count to 1,318, up from 800 a year ago.By the end of the year, the company will be merging with fellow Canadian cannabis producerAphria (NASDAQ:APHA) to create the biggest marijuana company globally, with $658 million in combined revenue during the past 12 months. Over the next two years, the two companies could realize up to 100 million Canadian dollars in acquisition synergies (such as joining corporate offices together).What's more, the two marijuana producers will have the biggest market share in Canada, accounting for 17% of all cannabis sales volume in the country. That's 7 percentage points higher than the next biggest leading competitor, which is Canopy Growth (NASDAQ:CGC).Should you give Tilray a shot?Right now, Tilray is pretty expensive, trading at 15 times revenue. Even some of the fastest-growing cannabis companies -- like Green Thumb Industries(OTC:GTBIF),Trulieve(OTC:TCNNF), and Curaleaf(OTC:CURLF) -- are only valued between 10 and 15 times sales. What makes Tilray special, however, is its vast international presence. The company has medical cannabis operations in over 17 countries.Over half of Aphria's CA$160.5 million in quarterly net sales comes from its distribution of cannabis to over 13,000 pharmacies in Germany. Additionally, the two companies also have a sizable presence in the U.S. Tilray's Manitoba subsidiary generates about $77 million per year in cannabidiol (CBD) revenue. Meanwhile, Aphria's SweetWater Brewing subsidiary posted $66 million in sales in 2019 and has its products in more than 29,000 restaurants, retailers, and bars nationwide.After the merger, Tilray will offer a near-complete collection of marijuana products, including flowers, pre-rolls, oils, capsules, vapes, edibles, beverages, and medical options, missing only cannabis-based pharmaceutical drugs. Given its opportunity to scale just about every segment of its operations on an international level, this is definitely a marijuana stock you don't want to miss.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":329034065,"gmtCreate":1615187428557,"gmtModify":1703485361737,"author":{"id":"3577663215566360","authorId":"3577663215566360","name":"ruii","avatar":"https://static.tigerbbs.com/62406c1ce9070559e3d0387107105cf8","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3577663215566360","idStr":"3577663215566360"},"htmlText":"Really worth?&nbsp;","listText":"Really worth?&nbsp;","text":"Really worth?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/329034065","repostId":2117666651,"repostType":4,"repost":{"id":"2117666651","pubTimestamp":1615185538,"share":"https://www.laohu8.com/m/news/2117666651?lang=&edition=full","pubTime":"2021-03-08 14:38","market":"us","language":"en","title":"Is Tilray Stock a Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2117666651","media":"Motley Fool","summary":"It's not the worst idea to invest in the world's largest marijuana grower by revenue.","content":"<p>It's not the worst idea to invest in the world's largest marijuana grower by revenue.</p><p>Canadian weed giant&nbsp;<b>Tilray</b>&nbsp;was on a tear for much of 2020. Despite the stock market woes of the past week, its shares have gone up nearly 60% over the past 12 months, making it <a href=\"https://laohu8.com/S/AONE\">one</a> of the top performers in the industry benchmark&nbsp;<b>Horizons Marijuana Life Sciences Index ETF</b>, which returned 46% over the same period.</p><p>Investors have a lot to be thrilled about with Tilray, the most promising of which is its substantial international presence, which will become a game-changer as more countries legalize the recreational and medical use of cannabis. Let's investigate how Tilray can capitalize on marijuana's entry to the mainstream.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4e67c24b45ce1a24b947a25d187b0341\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p><p><b>An exciting cannabis company</b></p><p>Last year, Tilray grew its revenue by 26% from 2019, reaching $210.5 million. It is also near the finish line in terms of achieving profitability. During Q4 2020 (ended Dec. 31), its net loss narrowed to just $3 million from $219.8 million in the prior-year quarter.</p><p>The company terminated a bulk cannabis supply agreement, and as a result, only managed to sell 6,901 kilograms (kg) of dried cannabis in Q4 2020 compared to 15,039 kg in Q4 2019. However, Tilray is seeing more demand for high-priced, highly tetrahydrocannabinol (THC)-potent adult brands. The net selling price of its cannabis went up to $5.97 per gram compared to $1.88 a year earlier. Also, it brought its total store count to 1,318, up from 800 a year ago.</p><p>By the end of the year, the company will be merging with fellow Canadian cannabis producer<b>Aphria</b> (NASDAQ:APHA) to create the biggest marijuana company globally, with $658 million in combined revenue during the past 12 months. Over the next two years, the two companies could realize up to 100 million Canadian dollars in acquisition synergies (such as joining corporate offices together).</p><p>What's more, the two marijuana producers will have the biggest market share in Canada, accounting for 17% of all cannabis sales volume in the country. That's 7 percentage points higher than the next biggest leading competitor, which is&nbsp;<b>Canopy Growth</b>&nbsp;(NASDAQ:CGC).</p><p><b>Should you give Tilray a shot?</b></p><p>Right now, Tilray is pretty expensive, trading at 15 times revenue. Even some of the fastest-growing cannabis companies -- like&nbsp;<b>Green Thumb Industries</b>(OTC:GTBIF),<b>Trulieve</b>(OTC:TCNNF), and&nbsp;<b>Curaleaf</b>(OTC:CURLF) -- are only valued between 10 and 15 times sales. What makes Tilray special,&nbsp;however, is its vast international presence. The company has medical cannabis operations in over 17 countries.</p><p>Over half of Aphria's CA$160.5 million in quarterly net sales comes from its distribution of cannabis to over 13,000 pharmacies in Germany. Additionally, the two companies also have a sizable presence in the U.S. Tilray's Manitoba subsidiary generates about $77 million per year in cannabidiol (CBD) revenue. Meanwhile, Aphria's SweetWater Brewing subsidiary posted $66 million in sales in 2019 and has its products in more than 29,000 restaurants, retailers, and bars nationwide.</p><p>After the merger, Tilray will offer a near-complete collection of marijuana products, including flowers, pre-rolls, oils, capsules, vapes, edibles, beverages, and medical options, missing only cannabis-based pharmaceutical drugs. Given its opportunity to scale just about every segment of its operations on an international level, this is definitely a marijuana stock you don't want to miss.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Tilray Stock a Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Tilray Stock a Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-08 14:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/07/is-tilray-stock-a-buy/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It's not the worst idea to invest in the world's largest marijuana grower by revenue.Canadian weed giant Tilray was on a tear for much of 2020. Despite the stock market woes of the past week, its ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/07/is-tilray-stock-a-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/03/07/is-tilray-stock-a-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2117666651","content_text":"It's not the worst idea to invest in the world's largest marijuana grower by revenue.Canadian weed giant Tilray was on a tear for much of 2020. Despite the stock market woes of the past week, its shares have gone up nearly 60% over the past 12 months, making it one of the top performers in the industry benchmark Horizons Marijuana Life Sciences Index ETF, which returned 46% over the same period.Investors have a lot to be thrilled about with Tilray, the most promising of which is its substantial international presence, which will become a game-changer as more countries legalize the recreational and medical use of cannabis. Let's investigate how Tilray can capitalize on marijuana's entry to the mainstream.Image source: Getty Images.An exciting cannabis companyLast year, Tilray grew its revenue by 26% from 2019, reaching $210.5 million. It is also near the finish line in terms of achieving profitability. During Q4 2020 (ended Dec. 31), its net loss narrowed to just $3 million from $219.8 million in the prior-year quarter.The company terminated a bulk cannabis supply agreement, and as a result, only managed to sell 6,901 kilograms (kg) of dried cannabis in Q4 2020 compared to 15,039 kg in Q4 2019. However, Tilray is seeing more demand for high-priced, highly tetrahydrocannabinol (THC)-potent adult brands. The net selling price of its cannabis went up to $5.97 per gram compared to $1.88 a year earlier. Also, it brought its total store count to 1,318, up from 800 a year ago.By the end of the year, the company will be merging with fellow Canadian cannabis producerAphria (NASDAQ:APHA) to create the biggest marijuana company globally, with $658 million in combined revenue during the past 12 months. Over the next two years, the two companies could realize up to 100 million Canadian dollars in acquisition synergies (such as joining corporate offices together).What's more, the two marijuana producers will have the biggest market share in Canada, accounting for 17% of all cannabis sales volume in the country. That's 7 percentage points higher than the next biggest leading competitor, which is Canopy Growth (NASDAQ:CGC).Should you give Tilray a shot?Right now, Tilray is pretty expensive, trading at 15 times revenue. Even some of the fastest-growing cannabis companies -- like Green Thumb Industries(OTC:GTBIF),Trulieve(OTC:TCNNF), and Curaleaf(OTC:CURLF) -- are only valued between 10 and 15 times sales. What makes Tilray special, however, is its vast international presence. The company has medical cannabis operations in over 17 countries.Over half of Aphria's CA$160.5 million in quarterly net sales comes from its distribution of cannabis to over 13,000 pharmacies in Germany. Additionally, the two companies also have a sizable presence in the U.S. Tilray's Manitoba subsidiary generates about $77 million per year in cannabidiol (CBD) revenue. Meanwhile, Aphria's SweetWater Brewing subsidiary posted $66 million in sales in 2019 and has its products in more than 29,000 restaurants, retailers, and bars nationwide.After the merger, Tilray will offer a near-complete collection of marijuana products, including flowers, pre-rolls, oils, capsules, vapes, edibles, beverages, and medical options, missing only cannabis-based pharmaceutical drugs. Given its opportunity to scale just about every segment of its operations on an international level, this is definitely a marijuana stock you don't want to miss.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3740403,"gmtCreate":1615187841579,"gmtModify":1635757419208,"authorId":3569978586500313,"author":{"id":3569978586500313,"idStr":"3569978586500313","authorId":3569978586500313,"name":"CSYNCTP06","avatar":"https://static.tigerbbs.com/4fd2aa5c3a3fb737be0567ef3f336a98","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":329034065,"type":1,"supId":0,"prevId":0,"content":"Not really","text":"Not really","html":"Not really"}],"langContent":"EN"},{"id":329097119,"gmtCreate":1615186300831,"gmtModify":1703485349429,"author":{"id":"3575104063835966","authorId":"3575104063835966","name":"ChickenRice","avatar":"https://static.tigerbbs.com/19ed11789cfde175d98ed256116047dd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3575104063835966","idStr":"3575104063835966"},"htmlText":"<a href=\"https://laohu8.com/S/TLRY\">$Tilray Inc.(TLRY)$</a>getting ready for 4/20, also known as week day.With more states in the U.S. getting Marijuana legalised both recreational and medicinal use. I see no exception that this is a far fetch long term investment in the long run.","listText":"<a href=\"https://laohu8.com/S/TLRY\">$Tilray Inc.(TLRY)$</a>getting ready for 4/20, also known as week day.With more states in the U.S. getting Marijuana legalised both recreational and medicinal use. I see no exception that this is a far fetch long term investment in the long run.","text":"$Tilray Inc.(TLRY)$getting ready for 4/20, also known as week day.With more states in the U.S. getting Marijuana legalised both recreational and medicinal use. I see no exception that this is a far fetch long term investment in the long run.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/329097119","repostId":2117666651,"repostType":4,"repost":{"id":"2117666651","pubTimestamp":1615185538,"share":"https://www.laohu8.com/m/news/2117666651?lang=&edition=full","pubTime":"2021-03-08 14:38","market":"us","language":"en","title":"Is Tilray Stock a Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2117666651","media":"Motley Fool","summary":"It's not the worst idea to invest in the world's largest marijuana grower by revenue.","content":"<p>It's not the worst idea to invest in the world's largest marijuana grower by revenue.</p><p>Canadian weed giant&nbsp;<b>Tilray</b>&nbsp;was on a tear for much of 2020. Despite the stock market woes of the past week, its shares have gone up nearly 60% over the past 12 months, making it <a href=\"https://laohu8.com/S/AONE\">one</a> of the top performers in the industry benchmark&nbsp;<b>Horizons Marijuana Life Sciences Index ETF</b>, which returned 46% over the same period.</p><p>Investors have a lot to be thrilled about with Tilray, the most promising of which is its substantial international presence, which will become a game-changer as more countries legalize the recreational and medical use of cannabis. Let's investigate how Tilray can capitalize on marijuana's entry to the mainstream.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4e67c24b45ce1a24b947a25d187b0341\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p><p><b>An exciting cannabis company</b></p><p>Last year, Tilray grew its revenue by 26% from 2019, reaching $210.5 million. It is also near the finish line in terms of achieving profitability. During Q4 2020 (ended Dec. 31), its net loss narrowed to just $3 million from $219.8 million in the prior-year quarter.</p><p>The company terminated a bulk cannabis supply agreement, and as a result, only managed to sell 6,901 kilograms (kg) of dried cannabis in Q4 2020 compared to 15,039 kg in Q4 2019. However, Tilray is seeing more demand for high-priced, highly tetrahydrocannabinol (THC)-potent adult brands. The net selling price of its cannabis went up to $5.97 per gram compared to $1.88 a year earlier. Also, it brought its total store count to 1,318, up from 800 a year ago.</p><p>By the end of the year, the company will be merging with fellow Canadian cannabis producer<b>Aphria</b> (NASDAQ:APHA) to create the biggest marijuana company globally, with $658 million in combined revenue during the past 12 months. Over the next two years, the two companies could realize up to 100 million Canadian dollars in acquisition synergies (such as joining corporate offices together).</p><p>What's more, the two marijuana producers will have the biggest market share in Canada, accounting for 17% of all cannabis sales volume in the country. That's 7 percentage points higher than the next biggest leading competitor, which is&nbsp;<b>Canopy Growth</b>&nbsp;(NASDAQ:CGC).</p><p><b>Should you give Tilray a shot?</b></p><p>Right now, Tilray is pretty expensive, trading at 15 times revenue. Even some of the fastest-growing cannabis companies -- like&nbsp;<b>Green Thumb Industries</b>(OTC:GTBIF),<b>Trulieve</b>(OTC:TCNNF), and&nbsp;<b>Curaleaf</b>(OTC:CURLF) -- are only valued between 10 and 15 times sales. What makes Tilray special,&nbsp;however, is its vast international presence. The company has medical cannabis operations in over 17 countries.</p><p>Over half of Aphria's CA$160.5 million in quarterly net sales comes from its distribution of cannabis to over 13,000 pharmacies in Germany. Additionally, the two companies also have a sizable presence in the U.S. Tilray's Manitoba subsidiary generates about $77 million per year in cannabidiol (CBD) revenue. Meanwhile, Aphria's SweetWater Brewing subsidiary posted $66 million in sales in 2019 and has its products in more than 29,000 restaurants, retailers, and bars nationwide.</p><p>After the merger, Tilray will offer a near-complete collection of marijuana products, including flowers, pre-rolls, oils, capsules, vapes, edibles, beverages, and medical options, missing only cannabis-based pharmaceutical drugs. Given its opportunity to scale just about every segment of its operations on an international level, this is definitely a marijuana stock you don't want to miss.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Tilray Stock a Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Tilray Stock a Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-08 14:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/07/is-tilray-stock-a-buy/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It's not the worst idea to invest in the world's largest marijuana grower by revenue.Canadian weed giant Tilray was on a tear for much of 2020. Despite the stock market woes of the past week, its ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/07/is-tilray-stock-a-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/03/07/is-tilray-stock-a-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2117666651","content_text":"It's not the worst idea to invest in the world's largest marijuana grower by revenue.Canadian weed giant Tilray was on a tear for much of 2020. Despite the stock market woes of the past week, its shares have gone up nearly 60% over the past 12 months, making it one of the top performers in the industry benchmark Horizons Marijuana Life Sciences Index ETF, which returned 46% over the same period.Investors have a lot to be thrilled about with Tilray, the most promising of which is its substantial international presence, which will become a game-changer as more countries legalize the recreational and medical use of cannabis. Let's investigate how Tilray can capitalize on marijuana's entry to the mainstream.Image source: Getty Images.An exciting cannabis companyLast year, Tilray grew its revenue by 26% from 2019, reaching $210.5 million. It is also near the finish line in terms of achieving profitability. During Q4 2020 (ended Dec. 31), its net loss narrowed to just $3 million from $219.8 million in the prior-year quarter.The company terminated a bulk cannabis supply agreement, and as a result, only managed to sell 6,901 kilograms (kg) of dried cannabis in Q4 2020 compared to 15,039 kg in Q4 2019. However, Tilray is seeing more demand for high-priced, highly tetrahydrocannabinol (THC)-potent adult brands. The net selling price of its cannabis went up to $5.97 per gram compared to $1.88 a year earlier. Also, it brought its total store count to 1,318, up from 800 a year ago.By the end of the year, the company will be merging with fellow Canadian cannabis producerAphria (NASDAQ:APHA) to create the biggest marijuana company globally, with $658 million in combined revenue during the past 12 months. Over the next two years, the two companies could realize up to 100 million Canadian dollars in acquisition synergies (such as joining corporate offices together).What's more, the two marijuana producers will have the biggest market share in Canada, accounting for 17% of all cannabis sales volume in the country. That's 7 percentage points higher than the next biggest leading competitor, which is Canopy Growth (NASDAQ:CGC).Should you give Tilray a shot?Right now, Tilray is pretty expensive, trading at 15 times revenue. Even some of the fastest-growing cannabis companies -- like Green Thumb Industries(OTC:GTBIF),Trulieve(OTC:TCNNF), and Curaleaf(OTC:CURLF) -- are only valued between 10 and 15 times sales. What makes Tilray special, however, is its vast international presence. The company has medical cannabis operations in over 17 countries.Over half of Aphria's CA$160.5 million in quarterly net sales comes from its distribution of cannabis to over 13,000 pharmacies in Germany. Additionally, the two companies also have a sizable presence in the U.S. Tilray's Manitoba subsidiary generates about $77 million per year in cannabidiol (CBD) revenue. Meanwhile, Aphria's SweetWater Brewing subsidiary posted $66 million in sales in 2019 and has its products in more than 29,000 restaurants, retailers, and bars nationwide.After the merger, Tilray will offer a near-complete collection of marijuana products, including flowers, pre-rolls, oils, capsules, vapes, edibles, beverages, and medical options, missing only cannabis-based pharmaceutical drugs. Given its opportunity to scale just about every segment of its operations on an international level, this is definitely a marijuana stock you don't want to miss.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3749525,"gmtCreate":1615273325823,"gmtModify":1635756965151,"authorId":3575104063835966,"author":{"id":3575104063835966,"idStr":"3575104063835966","authorId":3575104063835966,"name":"ChickenRice","avatar":"https://static.tigerbbs.com/19ed11789cfde175d98ed256116047dd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":329097119,"type":1,"supId":3748807,"prevId":0,"content":"4月20日是杂草日. 😅","text":"4月20日是杂草日. 😅","html":"4月20日是杂草日. 😅"},{"id":3769512,"gmtCreate":1615460180667,"gmtModify":1615460180667,"authorId":3521492743188918,"author":{"id":3521492743188918,"idStr":"3521492743188918","authorId":3521492743188918,"name":"penger_1247","avatar":"https://static.tigerbbs.com/a757a228ecaa14179f3faea663871cdf","vip":1,"crmLevel":9,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":329097119,"type":1,"supId":0,"prevId":0,"content":"拿住五年应该有不错的回报","text":"拿住五年应该有不错的回报","html":"拿住五年应该有不错的回报"},{"id":3748807,"gmtCreate":1615265100435,"gmtModify":1615265100435,"authorId":3569891020684074,"author":{"id":3569891020684074,"idStr":"3569891020684074","authorId":3569891020684074,"name":"AbC","avatar":"https://static.tigerbbs.com/5aa41b2f67f05a172f26af7c1425b3f5","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":329097119,"type":1,"supId":0,"prevId":0,"content":"4月20日是什么日子？","text":"4月20日是什么日子？","html":"4月20日是什么日子？"},{"id":3741165,"gmtCreate":1615194907659,"gmtModify":1615194907659,"authorId":3444732750101190,"author":{"id":3444732750101190,"idStr":"3444732750101190","authorId":3444732750101190,"name":"行天下639800","avatar":"https://static.laohu8.com/7a9872d82227fdf805e09770cb2961a8","vip":1,"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":329097119,"type":1,"supId":0,"prevId":0,"content":"这是理智的[强][强][强]","text":"这是理智的[强][强][强]","html":"这是理智的[强][强][强]"}],"langContent":"EN"},{"id":329094947,"gmtCreate":1615186104789,"gmtModify":1703485347350,"author":{"id":"3575205207637336","authorId":"3575205207637336","name":"weijie123","avatar":"https://static.tigerbbs.com/f79451a0e5ae21cfbd9c59c760eed0a7","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3575205207637336","idStr":"3575205207637336"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/329094947","repostId":2117666651,"repostType":4,"repost":{"id":"2117666651","pubTimestamp":1615185538,"share":"https://www.laohu8.com/m/news/2117666651?lang=&edition=full","pubTime":"2021-03-08 14:38","market":"us","language":"en","title":"Is Tilray Stock a Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2117666651","media":"Motley Fool","summary":"It's not the worst idea to invest in the world's largest marijuana grower by revenue.","content":"<p>It's not the worst idea to invest in the world's largest marijuana grower by revenue.</p><p>Canadian weed giant&nbsp;<b>Tilray</b>&nbsp;was on a tear for much of 2020. Despite the stock market woes of the past week, its shares have gone up nearly 60% over the past 12 months, making it <a href=\"https://laohu8.com/S/AONE\">one</a> of the top performers in the industry benchmark&nbsp;<b>Horizons Marijuana Life Sciences Index ETF</b>, which returned 46% over the same period.</p><p>Investors have a lot to be thrilled about with Tilray, the most promising of which is its substantial international presence, which will become a game-changer as more countries legalize the recreational and medical use of cannabis. Let's investigate how Tilray can capitalize on marijuana's entry to the mainstream.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4e67c24b45ce1a24b947a25d187b0341\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p><p><b>An exciting cannabis company</b></p><p>Last year, Tilray grew its revenue by 26% from 2019, reaching $210.5 million. It is also near the finish line in terms of achieving profitability. During Q4 2020 (ended Dec. 31), its net loss narrowed to just $3 million from $219.8 million in the prior-year quarter.</p><p>The company terminated a bulk cannabis supply agreement, and as a result, only managed to sell 6,901 kilograms (kg) of dried cannabis in Q4 2020 compared to 15,039 kg in Q4 2019. However, Tilray is seeing more demand for high-priced, highly tetrahydrocannabinol (THC)-potent adult brands. The net selling price of its cannabis went up to $5.97 per gram compared to $1.88 a year earlier. Also, it brought its total store count to 1,318, up from 800 a year ago.</p><p>By the end of the year, the company will be merging with fellow Canadian cannabis producer<b>Aphria</b> (NASDAQ:APHA) to create the biggest marijuana company globally, with $658 million in combined revenue during the past 12 months. Over the next two years, the two companies could realize up to 100 million Canadian dollars in acquisition synergies (such as joining corporate offices together).</p><p>What's more, the two marijuana producers will have the biggest market share in Canada, accounting for 17% of all cannabis sales volume in the country. That's 7 percentage points higher than the next biggest leading competitor, which is&nbsp;<b>Canopy Growth</b>&nbsp;(NASDAQ:CGC).</p><p><b>Should you give Tilray a shot?</b></p><p>Right now, Tilray is pretty expensive, trading at 15 times revenue. Even some of the fastest-growing cannabis companies -- like&nbsp;<b>Green Thumb Industries</b>(OTC:GTBIF),<b>Trulieve</b>(OTC:TCNNF), and&nbsp;<b>Curaleaf</b>(OTC:CURLF) -- are only valued between 10 and 15 times sales. What makes Tilray special,&nbsp;however, is its vast international presence. The company has medical cannabis operations in over 17 countries.</p><p>Over half of Aphria's CA$160.5 million in quarterly net sales comes from its distribution of cannabis to over 13,000 pharmacies in Germany. Additionally, the two companies also have a sizable presence in the U.S. Tilray's Manitoba subsidiary generates about $77 million per year in cannabidiol (CBD) revenue. Meanwhile, Aphria's SweetWater Brewing subsidiary posted $66 million in sales in 2019 and has its products in more than 29,000 restaurants, retailers, and bars nationwide.</p><p>After the merger, Tilray will offer a near-complete collection of marijuana products, including flowers, pre-rolls, oils, capsules, vapes, edibles, beverages, and medical options, missing only cannabis-based pharmaceutical drugs. Given its opportunity to scale just about every segment of its operations on an international level, this is definitely a marijuana stock you don't want to miss.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Tilray Stock a Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Tilray Stock a Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-08 14:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/07/is-tilray-stock-a-buy/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It's not the worst idea to invest in the world's largest marijuana grower by revenue.Canadian weed giant Tilray was on a tear for much of 2020. Despite the stock market woes of the past week, its ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/07/is-tilray-stock-a-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/03/07/is-tilray-stock-a-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2117666651","content_text":"It's not the worst idea to invest in the world's largest marijuana grower by revenue.Canadian weed giant Tilray was on a tear for much of 2020. Despite the stock market woes of the past week, its shares have gone up nearly 60% over the past 12 months, making it one of the top performers in the industry benchmark Horizons Marijuana Life Sciences Index ETF, which returned 46% over the same period.Investors have a lot to be thrilled about with Tilray, the most promising of which is its substantial international presence, which will become a game-changer as more countries legalize the recreational and medical use of cannabis. Let's investigate how Tilray can capitalize on marijuana's entry to the mainstream.Image source: Getty Images.An exciting cannabis companyLast year, Tilray grew its revenue by 26% from 2019, reaching $210.5 million. It is also near the finish line in terms of achieving profitability. During Q4 2020 (ended Dec. 31), its net loss narrowed to just $3 million from $219.8 million in the prior-year quarter.The company terminated a bulk cannabis supply agreement, and as a result, only managed to sell 6,901 kilograms (kg) of dried cannabis in Q4 2020 compared to 15,039 kg in Q4 2019. However, Tilray is seeing more demand for high-priced, highly tetrahydrocannabinol (THC)-potent adult brands. The net selling price of its cannabis went up to $5.97 per gram compared to $1.88 a year earlier. Also, it brought its total store count to 1,318, up from 800 a year ago.By the end of the year, the company will be merging with fellow Canadian cannabis producerAphria (NASDAQ:APHA) to create the biggest marijuana company globally, with $658 million in combined revenue during the past 12 months. Over the next two years, the two companies could realize up to 100 million Canadian dollars in acquisition synergies (such as joining corporate offices together).What's more, the two marijuana producers will have the biggest market share in Canada, accounting for 17% of all cannabis sales volume in the country. That's 7 percentage points higher than the next biggest leading competitor, which is Canopy Growth (NASDAQ:CGC).Should you give Tilray a shot?Right now, Tilray is pretty expensive, trading at 15 times revenue. Even some of the fastest-growing cannabis companies -- like Green Thumb Industries(OTC:GTBIF),Trulieve(OTC:TCNNF), and Curaleaf(OTC:CURLF) -- are only valued between 10 and 15 times sales. What makes Tilray special, however, is its vast international presence. The company has medical cannabis operations in over 17 countries.Over half of Aphria's CA$160.5 million in quarterly net sales comes from its distribution of cannabis to over 13,000 pharmacies in Germany. Additionally, the two companies also have a sizable presence in the U.S. Tilray's Manitoba subsidiary generates about $77 million per year in cannabidiol (CBD) revenue. Meanwhile, Aphria's SweetWater Brewing subsidiary posted $66 million in sales in 2019 and has its products in more than 29,000 restaurants, retailers, and bars nationwide.After the merger, Tilray will offer a near-complete collection of marijuana products, including flowers, pre-rolls, oils, capsules, vapes, edibles, beverages, and medical options, missing only cannabis-based pharmaceutical drugs. Given its opportunity to scale just about every segment of its operations on an international level, this is definitely a marijuana stock you don't want to miss.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":329098485,"gmtCreate":1615185850347,"gmtModify":1703485343189,"author":{"id":"3554803619527377","authorId":"3554803619527377","name":"vbjvvbb","avatar":"https://static.tigerbbs.com/8fb1b38f4354ec237a7cab99dbd46e94","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3554803619527377","idStr":"3554803619527377"},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/329098485","repostId":2117666651,"repostType":4,"repost":{"id":"2117666651","pubTimestamp":1615185538,"share":"https://www.laohu8.com/m/news/2117666651?lang=&edition=full","pubTime":"2021-03-08 14:38","market":"us","language":"en","title":"Is Tilray Stock a Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2117666651","media":"Motley Fool","summary":"It's not the worst idea to invest in the world's largest marijuana grower by revenue.","content":"<p>It's not the worst idea to invest in the world's largest marijuana grower by revenue.</p><p>Canadian weed giant&nbsp;<b>Tilray</b>&nbsp;was on a tear for much of 2020. Despite the stock market woes of the past week, its shares have gone up nearly 60% over the past 12 months, making it <a href=\"https://laohu8.com/S/AONE\">one</a> of the top performers in the industry benchmark&nbsp;<b>Horizons Marijuana Life Sciences Index ETF</b>, which returned 46% over the same period.</p><p>Investors have a lot to be thrilled about with Tilray, the most promising of which is its substantial international presence, which will become a game-changer as more countries legalize the recreational and medical use of cannabis. Let's investigate how Tilray can capitalize on marijuana's entry to the mainstream.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4e67c24b45ce1a24b947a25d187b0341\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p><p><b>An exciting cannabis company</b></p><p>Last year, Tilray grew its revenue by 26% from 2019, reaching $210.5 million. It is also near the finish line in terms of achieving profitability. During Q4 2020 (ended Dec. 31), its net loss narrowed to just $3 million from $219.8 million in the prior-year quarter.</p><p>The company terminated a bulk cannabis supply agreement, and as a result, only managed to sell 6,901 kilograms (kg) of dried cannabis in Q4 2020 compared to 15,039 kg in Q4 2019. However, Tilray is seeing more demand for high-priced, highly tetrahydrocannabinol (THC)-potent adult brands. The net selling price of its cannabis went up to $5.97 per gram compared to $1.88 a year earlier. Also, it brought its total store count to 1,318, up from 800 a year ago.</p><p>By the end of the year, the company will be merging with fellow Canadian cannabis producer<b>Aphria</b> (NASDAQ:APHA) to create the biggest marijuana company globally, with $658 million in combined revenue during the past 12 months. Over the next two years, the two companies could realize up to 100 million Canadian dollars in acquisition synergies (such as joining corporate offices together).</p><p>What's more, the two marijuana producers will have the biggest market share in Canada, accounting for 17% of all cannabis sales volume in the country. That's 7 percentage points higher than the next biggest leading competitor, which is&nbsp;<b>Canopy Growth</b>&nbsp;(NASDAQ:CGC).</p><p><b>Should you give Tilray a shot?</b></p><p>Right now, Tilray is pretty expensive, trading at 15 times revenue. Even some of the fastest-growing cannabis companies -- like&nbsp;<b>Green Thumb Industries</b>(OTC:GTBIF),<b>Trulieve</b>(OTC:TCNNF), and&nbsp;<b>Curaleaf</b>(OTC:CURLF) -- are only valued between 10 and 15 times sales. What makes Tilray special,&nbsp;however, is its vast international presence. The company has medical cannabis operations in over 17 countries.</p><p>Over half of Aphria's CA$160.5 million in quarterly net sales comes from its distribution of cannabis to over 13,000 pharmacies in Germany. Additionally, the two companies also have a sizable presence in the U.S. Tilray's Manitoba subsidiary generates about $77 million per year in cannabidiol (CBD) revenue. Meanwhile, Aphria's SweetWater Brewing subsidiary posted $66 million in sales in 2019 and has its products in more than 29,000 restaurants, retailers, and bars nationwide.</p><p>After the merger, Tilray will offer a near-complete collection of marijuana products, including flowers, pre-rolls, oils, capsules, vapes, edibles, beverages, and medical options, missing only cannabis-based pharmaceutical drugs. Given its opportunity to scale just about every segment of its operations on an international level, this is definitely a marijuana stock you don't want to miss.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Tilray Stock a Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Tilray Stock a Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-08 14:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/07/is-tilray-stock-a-buy/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It's not the worst idea to invest in the world's largest marijuana grower by revenue.Canadian weed giant Tilray was on a tear for much of 2020. Despite the stock market woes of the past week, its ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/07/is-tilray-stock-a-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/03/07/is-tilray-stock-a-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2117666651","content_text":"It's not the worst idea to invest in the world's largest marijuana grower by revenue.Canadian weed giant Tilray was on a tear for much of 2020. Despite the stock market woes of the past week, its shares have gone up nearly 60% over the past 12 months, making it one of the top performers in the industry benchmark Horizons Marijuana Life Sciences Index ETF, which returned 46% over the same period.Investors have a lot to be thrilled about with Tilray, the most promising of which is its substantial international presence, which will become a game-changer as more countries legalize the recreational and medical use of cannabis. Let's investigate how Tilray can capitalize on marijuana's entry to the mainstream.Image source: Getty Images.An exciting cannabis companyLast year, Tilray grew its revenue by 26% from 2019, reaching $210.5 million. It is also near the finish line in terms of achieving profitability. During Q4 2020 (ended Dec. 31), its net loss narrowed to just $3 million from $219.8 million in the prior-year quarter.The company terminated a bulk cannabis supply agreement, and as a result, only managed to sell 6,901 kilograms (kg) of dried cannabis in Q4 2020 compared to 15,039 kg in Q4 2019. However, Tilray is seeing more demand for high-priced, highly tetrahydrocannabinol (THC)-potent adult brands. The net selling price of its cannabis went up to $5.97 per gram compared to $1.88 a year earlier. Also, it brought its total store count to 1,318, up from 800 a year ago.By the end of the year, the company will be merging with fellow Canadian cannabis producerAphria (NASDAQ:APHA) to create the biggest marijuana company globally, with $658 million in combined revenue during the past 12 months. Over the next two years, the two companies could realize up to 100 million Canadian dollars in acquisition synergies (such as joining corporate offices together).What's more, the two marijuana producers will have the biggest market share in Canada, accounting for 17% of all cannabis sales volume in the country. That's 7 percentage points higher than the next biggest leading competitor, which is Canopy Growth (NASDAQ:CGC).Should you give Tilray a shot?Right now, Tilray is pretty expensive, trading at 15 times revenue. Even some of the fastest-growing cannabis companies -- like Green Thumb Industries(OTC:GTBIF),Trulieve(OTC:TCNNF), and Curaleaf(OTC:CURLF) -- are only valued between 10 and 15 times sales. What makes Tilray special, however, is its vast international presence. The company has medical cannabis operations in over 17 countries.Over half of Aphria's CA$160.5 million in quarterly net sales comes from its distribution of cannabis to over 13,000 pharmacies in Germany. Additionally, the two companies also have a sizable presence in the U.S. Tilray's Manitoba subsidiary generates about $77 million per year in cannabidiol (CBD) revenue. Meanwhile, Aphria's SweetWater Brewing subsidiary posted $66 million in sales in 2019 and has its products in more than 29,000 restaurants, retailers, and bars nationwide.After the merger, Tilray will offer a near-complete collection of marijuana products, including flowers, pre-rolls, oils, capsules, vapes, edibles, beverages, and medical options, missing only cannabis-based pharmaceutical drugs. Given its opportunity to scale just about every segment of its operations on an international level, this is definitely a marijuana stock you don't want to miss.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":329098123,"gmtCreate":1615185827662,"gmtModify":1703485342496,"author":{"id":"3554803619527377","authorId":"3554803619527377","name":"vbjvvbb","avatar":"https://static.tigerbbs.com/8fb1b38f4354ec237a7cab99dbd46e94","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3554803619527377","idStr":"3554803619527377"},"htmlText":"Omg","listText":"Omg","text":"Omg","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/329098123","repostId":2117666651,"repostType":4,"repost":{"id":"2117666651","pubTimestamp":1615185538,"share":"https://www.laohu8.com/m/news/2117666651?lang=&edition=full","pubTime":"2021-03-08 14:38","market":"us","language":"en","title":"Is Tilray Stock a Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2117666651","media":"Motley Fool","summary":"It's not the worst idea to invest in the world's largest marijuana grower by revenue.","content":"<p>It's not the worst idea to invest in the world's largest marijuana grower by revenue.</p><p>Canadian weed giant&nbsp;<b>Tilray</b>&nbsp;was on a tear for much of 2020. Despite the stock market woes of the past week, its shares have gone up nearly 60% over the past 12 months, making it <a href=\"https://laohu8.com/S/AONE\">one</a> of the top performers in the industry benchmark&nbsp;<b>Horizons Marijuana Life Sciences Index ETF</b>, which returned 46% over the same period.</p><p>Investors have a lot to be thrilled about with Tilray, the most promising of which is its substantial international presence, which will become a game-changer as more countries legalize the recreational and medical use of cannabis. Let's investigate how Tilray can capitalize on marijuana's entry to the mainstream.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4e67c24b45ce1a24b947a25d187b0341\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p><p><b>An exciting cannabis company</b></p><p>Last year, Tilray grew its revenue by 26% from 2019, reaching $210.5 million. It is also near the finish line in terms of achieving profitability. During Q4 2020 (ended Dec. 31), its net loss narrowed to just $3 million from $219.8 million in the prior-year quarter.</p><p>The company terminated a bulk cannabis supply agreement, and as a result, only managed to sell 6,901 kilograms (kg) of dried cannabis in Q4 2020 compared to 15,039 kg in Q4 2019. However, Tilray is seeing more demand for high-priced, highly tetrahydrocannabinol (THC)-potent adult brands. The net selling price of its cannabis went up to $5.97 per gram compared to $1.88 a year earlier. Also, it brought its total store count to 1,318, up from 800 a year ago.</p><p>By the end of the year, the company will be merging with fellow Canadian cannabis producer<b>Aphria</b> (NASDAQ:APHA) to create the biggest marijuana company globally, with $658 million in combined revenue during the past 12 months. Over the next two years, the two companies could realize up to 100 million Canadian dollars in acquisition synergies (such as joining corporate offices together).</p><p>What's more, the two marijuana producers will have the biggest market share in Canada, accounting for 17% of all cannabis sales volume in the country. That's 7 percentage points higher than the next biggest leading competitor, which is&nbsp;<b>Canopy Growth</b>&nbsp;(NASDAQ:CGC).</p><p><b>Should you give Tilray a shot?</b></p><p>Right now, Tilray is pretty expensive, trading at 15 times revenue. Even some of the fastest-growing cannabis companies -- like&nbsp;<b>Green Thumb Industries</b>(OTC:GTBIF),<b>Trulieve</b>(OTC:TCNNF), and&nbsp;<b>Curaleaf</b>(OTC:CURLF) -- are only valued between 10 and 15 times sales. What makes Tilray special,&nbsp;however, is its vast international presence. The company has medical cannabis operations in over 17 countries.</p><p>Over half of Aphria's CA$160.5 million in quarterly net sales comes from its distribution of cannabis to over 13,000 pharmacies in Germany. Additionally, the two companies also have a sizable presence in the U.S. Tilray's Manitoba subsidiary generates about $77 million per year in cannabidiol (CBD) revenue. Meanwhile, Aphria's SweetWater Brewing subsidiary posted $66 million in sales in 2019 and has its products in more than 29,000 restaurants, retailers, and bars nationwide.</p><p>After the merger, Tilray will offer a near-complete collection of marijuana products, including flowers, pre-rolls, oils, capsules, vapes, edibles, beverages, and medical options, missing only cannabis-based pharmaceutical drugs. Given its opportunity to scale just about every segment of its operations on an international level, this is definitely a marijuana stock you don't want to miss.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Tilray Stock a Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Tilray Stock a Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-08 14:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/07/is-tilray-stock-a-buy/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It's not the worst idea to invest in the world's largest marijuana grower by revenue.Canadian weed giant Tilray was on a tear for much of 2020. Despite the stock market woes of the past week, its ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/07/is-tilray-stock-a-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/03/07/is-tilray-stock-a-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2117666651","content_text":"It's not the worst idea to invest in the world's largest marijuana grower by revenue.Canadian weed giant Tilray was on a tear for much of 2020. Despite the stock market woes of the past week, its shares have gone up nearly 60% over the past 12 months, making it one of the top performers in the industry benchmark Horizons Marijuana Life Sciences Index ETF, which returned 46% over the same period.Investors have a lot to be thrilled about with Tilray, the most promising of which is its substantial international presence, which will become a game-changer as more countries legalize the recreational and medical use of cannabis. Let's investigate how Tilray can capitalize on marijuana's entry to the mainstream.Image source: Getty Images.An exciting cannabis companyLast year, Tilray grew its revenue by 26% from 2019, reaching $210.5 million. It is also near the finish line in terms of achieving profitability. During Q4 2020 (ended Dec. 31), its net loss narrowed to just $3 million from $219.8 million in the prior-year quarter.The company terminated a bulk cannabis supply agreement, and as a result, only managed to sell 6,901 kilograms (kg) of dried cannabis in Q4 2020 compared to 15,039 kg in Q4 2019. However, Tilray is seeing more demand for high-priced, highly tetrahydrocannabinol (THC)-potent adult brands. The net selling price of its cannabis went up to $5.97 per gram compared to $1.88 a year earlier. Also, it brought its total store count to 1,318, up from 800 a year ago.By the end of the year, the company will be merging with fellow Canadian cannabis producerAphria (NASDAQ:APHA) to create the biggest marijuana company globally, with $658 million in combined revenue during the past 12 months. Over the next two years, the two companies could realize up to 100 million Canadian dollars in acquisition synergies (such as joining corporate offices together).What's more, the two marijuana producers will have the biggest market share in Canada, accounting for 17% of all cannabis sales volume in the country. That's 7 percentage points higher than the next biggest leading competitor, which is Canopy Growth (NASDAQ:CGC).Should you give Tilray a shot?Right now, Tilray is pretty expensive, trading at 15 times revenue. Even some of the fastest-growing cannabis companies -- like Green Thumb Industries(OTC:GTBIF),Trulieve(OTC:TCNNF), and Curaleaf(OTC:CURLF) -- are only valued between 10 and 15 times sales. What makes Tilray special, however, is its vast international presence. The company has medical cannabis operations in over 17 countries.Over half of Aphria's CA$160.5 million in quarterly net sales comes from its distribution of cannabis to over 13,000 pharmacies in Germany. Additionally, the two companies also have a sizable presence in the U.S. Tilray's Manitoba subsidiary generates about $77 million per year in cannabidiol (CBD) revenue. Meanwhile, Aphria's SweetWater Brewing subsidiary posted $66 million in sales in 2019 and has its products in more than 29,000 restaurants, retailers, and bars nationwide.After the merger, Tilray will offer a near-complete collection of marijuana products, including flowers, pre-rolls, oils, capsules, vapes, edibles, beverages, and medical options, missing only cannabis-based pharmaceutical drugs. Given its opportunity to scale just about every segment of its operations on an international level, this is definitely a marijuana stock you don't want to miss.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":329093760,"gmtCreate":1615185708250,"gmtModify":1703485340242,"author":{"id":"3551655093075927","authorId":"3551655093075927","name":"KLS","avatar":"https://static.tigerbbs.com/60fe00969bbce4cfecf0d17a38c77628","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3551655093075927","idStr":"3551655093075927"},"htmlText":"Pls like n comment","listText":"Pls like n comment","text":"Pls like n comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/329093760","repostId":2117666651,"repostType":4,"repost":{"id":"2117666651","pubTimestamp":1615185538,"share":"https://www.laohu8.com/m/news/2117666651?lang=&edition=full","pubTime":"2021-03-08 14:38","market":"us","language":"en","title":"Is Tilray Stock a Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2117666651","media":"Motley Fool","summary":"It's not the worst idea to invest in the world's largest marijuana grower by revenue.","content":"<p>It's not the worst idea to invest in the world's largest marijuana grower by revenue.</p><p>Canadian weed giant&nbsp;<b>Tilray</b>&nbsp;was on a tear for much of 2020. Despite the stock market woes of the past week, its shares have gone up nearly 60% over the past 12 months, making it <a href=\"https://laohu8.com/S/AONE\">one</a> of the top performers in the industry benchmark&nbsp;<b>Horizons Marijuana Life Sciences Index ETF</b>, which returned 46% over the same period.</p><p>Investors have a lot to be thrilled about with Tilray, the most promising of which is its substantial international presence, which will become a game-changer as more countries legalize the recreational and medical use of cannabis. Let's investigate how Tilray can capitalize on marijuana's entry to the mainstream.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4e67c24b45ce1a24b947a25d187b0341\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p><p><b>An exciting cannabis company</b></p><p>Last year, Tilray grew its revenue by 26% from 2019, reaching $210.5 million. It is also near the finish line in terms of achieving profitability. During Q4 2020 (ended Dec. 31), its net loss narrowed to just $3 million from $219.8 million in the prior-year quarter.</p><p>The company terminated a bulk cannabis supply agreement, and as a result, only managed to sell 6,901 kilograms (kg) of dried cannabis in Q4 2020 compared to 15,039 kg in Q4 2019. However, Tilray is seeing more demand for high-priced, highly tetrahydrocannabinol (THC)-potent adult brands. The net selling price of its cannabis went up to $5.97 per gram compared to $1.88 a year earlier. Also, it brought its total store count to 1,318, up from 800 a year ago.</p><p>By the end of the year, the company will be merging with fellow Canadian cannabis producer<b>Aphria</b> (NASDAQ:APHA) to create the biggest marijuana company globally, with $658 million in combined revenue during the past 12 months. Over the next two years, the two companies could realize up to 100 million Canadian dollars in acquisition synergies (such as joining corporate offices together).</p><p>What's more, the two marijuana producers will have the biggest market share in Canada, accounting for 17% of all cannabis sales volume in the country. That's 7 percentage points higher than the next biggest leading competitor, which is&nbsp;<b>Canopy Growth</b>&nbsp;(NASDAQ:CGC).</p><p><b>Should you give Tilray a shot?</b></p><p>Right now, Tilray is pretty expensive, trading at 15 times revenue. Even some of the fastest-growing cannabis companies -- like&nbsp;<b>Green Thumb Industries</b>(OTC:GTBIF),<b>Trulieve</b>(OTC:TCNNF), and&nbsp;<b>Curaleaf</b>(OTC:CURLF) -- are only valued between 10 and 15 times sales. What makes Tilray special,&nbsp;however, is its vast international presence. The company has medical cannabis operations in over 17 countries.</p><p>Over half of Aphria's CA$160.5 million in quarterly net sales comes from its distribution of cannabis to over 13,000 pharmacies in Germany. Additionally, the two companies also have a sizable presence in the U.S. Tilray's Manitoba subsidiary generates about $77 million per year in cannabidiol (CBD) revenue. Meanwhile, Aphria's SweetWater Brewing subsidiary posted $66 million in sales in 2019 and has its products in more than 29,000 restaurants, retailers, and bars nationwide.</p><p>After the merger, Tilray will offer a near-complete collection of marijuana products, including flowers, pre-rolls, oils, capsules, vapes, edibles, beverages, and medical options, missing only cannabis-based pharmaceutical drugs. Given its opportunity to scale just about every segment of its operations on an international level, this is definitely a marijuana stock you don't want to miss.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Tilray Stock a Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Tilray Stock a Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-08 14:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/07/is-tilray-stock-a-buy/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It's not the worst idea to invest in the world's largest marijuana grower by revenue.Canadian weed giant Tilray was on a tear for much of 2020. Despite the stock market woes of the past week, its ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/07/is-tilray-stock-a-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/03/07/is-tilray-stock-a-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2117666651","content_text":"It's not the worst idea to invest in the world's largest marijuana grower by revenue.Canadian weed giant Tilray was on a tear for much of 2020. Despite the stock market woes of the past week, its shares have gone up nearly 60% over the past 12 months, making it one of the top performers in the industry benchmark Horizons Marijuana Life Sciences Index ETF, which returned 46% over the same period.Investors have a lot to be thrilled about with Tilray, the most promising of which is its substantial international presence, which will become a game-changer as more countries legalize the recreational and medical use of cannabis. Let's investigate how Tilray can capitalize on marijuana's entry to the mainstream.Image source: Getty Images.An exciting cannabis companyLast year, Tilray grew its revenue by 26% from 2019, reaching $210.5 million. It is also near the finish line in terms of achieving profitability. During Q4 2020 (ended Dec. 31), its net loss narrowed to just $3 million from $219.8 million in the prior-year quarter.The company terminated a bulk cannabis supply agreement, and as a result, only managed to sell 6,901 kilograms (kg) of dried cannabis in Q4 2020 compared to 15,039 kg in Q4 2019. However, Tilray is seeing more demand for high-priced, highly tetrahydrocannabinol (THC)-potent adult brands. The net selling price of its cannabis went up to $5.97 per gram compared to $1.88 a year earlier. Also, it brought its total store count to 1,318, up from 800 a year ago.By the end of the year, the company will be merging with fellow Canadian cannabis producerAphria (NASDAQ:APHA) to create the biggest marijuana company globally, with $658 million in combined revenue during the past 12 months. Over the next two years, the two companies could realize up to 100 million Canadian dollars in acquisition synergies (such as joining corporate offices together).What's more, the two marijuana producers will have the biggest market share in Canada, accounting for 17% of all cannabis sales volume in the country. That's 7 percentage points higher than the next biggest leading competitor, which is Canopy Growth (NASDAQ:CGC).Should you give Tilray a shot?Right now, Tilray is pretty expensive, trading at 15 times revenue. Even some of the fastest-growing cannabis companies -- like Green Thumb Industries(OTC:GTBIF),Trulieve(OTC:TCNNF), and Curaleaf(OTC:CURLF) -- are only valued between 10 and 15 times sales. What makes Tilray special, however, is its vast international presence. The company has medical cannabis operations in over 17 countries.Over half of Aphria's CA$160.5 million in quarterly net sales comes from its distribution of cannabis to over 13,000 pharmacies in Germany. Additionally, the two companies also have a sizable presence in the U.S. Tilray's Manitoba subsidiary generates about $77 million per year in cannabidiol (CBD) revenue. Meanwhile, Aphria's SweetWater Brewing subsidiary posted $66 million in sales in 2019 and has its products in more than 29,000 restaurants, retailers, and bars nationwide.After the merger, Tilray will offer a near-complete collection of marijuana products, including flowers, pre-rolls, oils, capsules, vapes, edibles, beverages, and medical options, missing only cannabis-based pharmaceutical drugs. Given its opportunity to scale just about every segment of its operations on an international level, this is definitely a marijuana stock you don't want to miss.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":329093635,"gmtCreate":1615185616127,"gmtModify":1703485339545,"author":{"id":"3555312962232191","authorId":"3555312962232191","name":"elite","avatar":"https://static.tigerbbs.com/2601d446a3f18f0e9bf7927e9dc30a0e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3555312962232191","idStr":"3555312962232191"},"htmlText":"Please help to comment","listText":"Please help to comment","text":"Please help to comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/329093635","repostId":2117666651,"repostType":4,"repost":{"id":"2117666651","pubTimestamp":1615185538,"share":"https://www.laohu8.com/m/news/2117666651?lang=&edition=full","pubTime":"2021-03-08 14:38","market":"us","language":"en","title":"Is Tilray Stock a Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2117666651","media":"Motley Fool","summary":"It's not the worst idea to invest in the world's largest marijuana grower by revenue.","content":"<p>It's not the worst idea to invest in the world's largest marijuana grower by revenue.</p><p>Canadian weed giant&nbsp;<b>Tilray</b>&nbsp;was on a tear for much of 2020. Despite the stock market woes of the past week, its shares have gone up nearly 60% over the past 12 months, making it <a href=\"https://laohu8.com/S/AONE\">one</a> of the top performers in the industry benchmark&nbsp;<b>Horizons Marijuana Life Sciences Index ETF</b>, which returned 46% over the same period.</p><p>Investors have a lot to be thrilled about with Tilray, the most promising of which is its substantial international presence, which will become a game-changer as more countries legalize the recreational and medical use of cannabis. Let's investigate how Tilray can capitalize on marijuana's entry to the mainstream.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4e67c24b45ce1a24b947a25d187b0341\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p><p><b>An exciting cannabis company</b></p><p>Last year, Tilray grew its revenue by 26% from 2019, reaching $210.5 million. It is also near the finish line in terms of achieving profitability. During Q4 2020 (ended Dec. 31), its net loss narrowed to just $3 million from $219.8 million in the prior-year quarter.</p><p>The company terminated a bulk cannabis supply agreement, and as a result, only managed to sell 6,901 kilograms (kg) of dried cannabis in Q4 2020 compared to 15,039 kg in Q4 2019. However, Tilray is seeing more demand for high-priced, highly tetrahydrocannabinol (THC)-potent adult brands. The net selling price of its cannabis went up to $5.97 per gram compared to $1.88 a year earlier. Also, it brought its total store count to 1,318, up from 800 a year ago.</p><p>By the end of the year, the company will be merging with fellow Canadian cannabis producer<b>Aphria</b> (NASDAQ:APHA) to create the biggest marijuana company globally, with $658 million in combined revenue during the past 12 months. Over the next two years, the two companies could realize up to 100 million Canadian dollars in acquisition synergies (such as joining corporate offices together).</p><p>What's more, the two marijuana producers will have the biggest market share in Canada, accounting for 17% of all cannabis sales volume in the country. That's 7 percentage points higher than the next biggest leading competitor, which is&nbsp;<b>Canopy Growth</b>&nbsp;(NASDAQ:CGC).</p><p><b>Should you give Tilray a shot?</b></p><p>Right now, Tilray is pretty expensive, trading at 15 times revenue. Even some of the fastest-growing cannabis companies -- like&nbsp;<b>Green Thumb Industries</b>(OTC:GTBIF),<b>Trulieve</b>(OTC:TCNNF), and&nbsp;<b>Curaleaf</b>(OTC:CURLF) -- are only valued between 10 and 15 times sales. What makes Tilray special,&nbsp;however, is its vast international presence. The company has medical cannabis operations in over 17 countries.</p><p>Over half of Aphria's CA$160.5 million in quarterly net sales comes from its distribution of cannabis to over 13,000 pharmacies in Germany. Additionally, the two companies also have a sizable presence in the U.S. Tilray's Manitoba subsidiary generates about $77 million per year in cannabidiol (CBD) revenue. Meanwhile, Aphria's SweetWater Brewing subsidiary posted $66 million in sales in 2019 and has its products in more than 29,000 restaurants, retailers, and bars nationwide.</p><p>After the merger, Tilray will offer a near-complete collection of marijuana products, including flowers, pre-rolls, oils, capsules, vapes, edibles, beverages, and medical options, missing only cannabis-based pharmaceutical drugs. Given its opportunity to scale just about every segment of its operations on an international level, this is definitely a marijuana stock you don't want to miss.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Tilray Stock a Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Tilray Stock a Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-08 14:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/07/is-tilray-stock-a-buy/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It's not the worst idea to invest in the world's largest marijuana grower by revenue.Canadian weed giant Tilray was on a tear for much of 2020. Despite the stock market woes of the past week, its ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/07/is-tilray-stock-a-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/03/07/is-tilray-stock-a-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2117666651","content_text":"It's not the worst idea to invest in the world's largest marijuana grower by revenue.Canadian weed giant Tilray was on a tear for much of 2020. Despite the stock market woes of the past week, its shares have gone up nearly 60% over the past 12 months, making it one of the top performers in the industry benchmark Horizons Marijuana Life Sciences Index ETF, which returned 46% over the same period.Investors have a lot to be thrilled about with Tilray, the most promising of which is its substantial international presence, which will become a game-changer as more countries legalize the recreational and medical use of cannabis. Let's investigate how Tilray can capitalize on marijuana's entry to the mainstream.Image source: Getty Images.An exciting cannabis companyLast year, Tilray grew its revenue by 26% from 2019, reaching $210.5 million. It is also near the finish line in terms of achieving profitability. During Q4 2020 (ended Dec. 31), its net loss narrowed to just $3 million from $219.8 million in the prior-year quarter.The company terminated a bulk cannabis supply agreement, and as a result, only managed to sell 6,901 kilograms (kg) of dried cannabis in Q4 2020 compared to 15,039 kg in Q4 2019. However, Tilray is seeing more demand for high-priced, highly tetrahydrocannabinol (THC)-potent adult brands. The net selling price of its cannabis went up to $5.97 per gram compared to $1.88 a year earlier. Also, it brought its total store count to 1,318, up from 800 a year ago.By the end of the year, the company will be merging with fellow Canadian cannabis producerAphria (NASDAQ:APHA) to create the biggest marijuana company globally, with $658 million in combined revenue during the past 12 months. Over the next two years, the two companies could realize up to 100 million Canadian dollars in acquisition synergies (such as joining corporate offices together).What's more, the two marijuana producers will have the biggest market share in Canada, accounting for 17% of all cannabis sales volume in the country. That's 7 percentage points higher than the next biggest leading competitor, which is Canopy Growth (NASDAQ:CGC).Should you give Tilray a shot?Right now, Tilray is pretty expensive, trading at 15 times revenue. Even some of the fastest-growing cannabis companies -- like Green Thumb Industries(OTC:GTBIF),Trulieve(OTC:TCNNF), and Curaleaf(OTC:CURLF) -- are only valued between 10 and 15 times sales. What makes Tilray special, however, is its vast international presence. The company has medical cannabis operations in over 17 countries.Over half of Aphria's CA$160.5 million in quarterly net sales comes from its distribution of cannabis to over 13,000 pharmacies in Germany. Additionally, the two companies also have a sizable presence in the U.S. Tilray's Manitoba subsidiary generates about $77 million per year in cannabidiol (CBD) revenue. Meanwhile, Aphria's SweetWater Brewing subsidiary posted $66 million in sales in 2019 and has its products in more than 29,000 restaurants, retailers, and bars nationwide.After the merger, Tilray will offer a near-complete collection of marijuana products, including flowers, pre-rolls, oils, capsules, vapes, edibles, beverages, and medical options, missing only cannabis-based pharmaceutical drugs. Given its opportunity to scale just about every segment of its operations on an international level, this is definitely a marijuana stock you don't want to miss.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3740246,"gmtCreate":1615185731010,"gmtModify":1635757425707,"authorId":3551655093075927,"author":{"id":3551655093075927,"idStr":"3551655093075927","authorId":3551655093075927,"name":"KLS","avatar":"https://static.tigerbbs.com/60fe00969bbce4cfecf0d17a38c77628","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":329093635,"type":1,"supId":0,"prevId":0,"content":"pls like n <u>cimment</u>","text":"pls like n <u>cimment</u>","html":"pls like n <u>cimment</u>"},{"id":3744866,"gmtCreate":1615219774392,"gmtModify":1635757213652,"authorId":3565081661382277,"author":{"id":3565081661382277,"idStr":"3565081661382277","authorId":3565081661382277,"name":"Mm101","avatar":"https://static.tigerbbs.com/01758aa877d9e5a9767d24de3a4e2ff1","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":329093635,"type":1,"supId":0,"prevId":0,"content":"Yes","text":"Yes","html":"Yes"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":8,"commentSize":7,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false}}